SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 5

Multitarget therapy versus intravenous cyclophosphamide in the induction treatment of lupus nephritis: a metaanalysis of randomized controlled trials

Jin DENG
Lei LUO
Lin ZHU
Huan XIE
Hongping XIE
Pages
901–910
Publication Date
2018-10-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The metaanalysis revealed that overall multitarget therapy is more effective at inducing complete renal remission compared with IVC (RR: 1.94, 95% CI: 1.61-2.33; P < 0.00001).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Multitarget therapy for lupus nephritis (LN) remains in its exploratory phrase and the recent evidence is insufficient.
📊
Key Findings & Data:Results: In total, we identified 8 trials including 801 patients.
💡
Conclusion & Impact:The metaanalysis revealed that overall multitarget therapy is more effective at inducing complete renal remission compared with IVC (RR: 1.94, 95% CI: 1.61-2.33; P < 0.00001).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Lupus nephritis · cyclophosphamide · mycophenolate mofetil

Abstract

Background/aim: Multitarget therapy for lupus nephritis (LN) remains in its exploratory phrase and the recent evidence is insufficient. This study aimed to evaluate the efficacy and safety of mycophenolate mofetil (MMF), tacrolimus (TAC), and steroids (multitarget therapy) versus intravenous cyclophosphamide (IVC) and steroids in induction treatment of LN. Materials and methods: We searched for randomized controlled trials of MMF plus TAC versus IVC in LN using PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, the China Biology Medicine Database, and the China National Knowledge Infrastructure Database. We assessed the retrieved citations and selected studies according to predefined inclusion and exclusion criteria. Results: In total, we identified 8 trials including 801 patients. The metaanalysis revealed that overall multitarget therapy is more effective at inducing complete renal remission compared with IVC (RR: 1.94, 95% CI: 1.61-2.33; P < 0.00001). In terms of LN classification, multitarget therapy exhibited superiority compared with IVC for inducing complete remission of class IV LN (RR: 1.52, 95% CI: 1.10- 2.08; P = 0.01), class V LN (RR: 4.24, 95% CI: 1.30-13.88; P = 0.02), and class V+IV LN (RR: 2.29, 95% CI: 1.45-3.62; P = 0.0004); however, no superiority was noted for class III LN or class V+III LN. The rates of gastrointestinal symptoms, abnormal liver function, leukopenia, and irregular menstruation were significantly reduced in the multitarget therapy group compared with the IVC group for LN. Nevertheless, the multitarget therapy group more frequently exhibited new-onset hypertension compared with the IVC group. Conclusion: Multitarget therapy is more effective than IVC in the induction treatment of LN in Chinese patients and exhibits a better safety profile.

🔖

Cite This Article

DENG, J., LUO, L., ZHU, L., XIE, H., XIE, H. (2018). Multitarget therapy versus intravenous cyclophosphamide in the induction treatment of lupus nephritis: a metaanalysis of randomized controlled trials. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 5, 901–910. https://ajindex.com/articles/113466

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Jaryal A, Vikrant S. Current status of lupus nephritis. Indian J Med Res 2017; 145: 167-178.
  2. Yap DY, Tang CS, Ma MK, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transpl 2012; 27: 3248-3254.
  3. Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephro 2008; 3: 46-53.
  4. Hanaoka H, Kiyokawa T, Iida H, Ishimori K, Takakuwa Y, Okazaki T, Yamada H, Ichikawa D, Shirai S, Koike J et al. Comparison of renal response to four different induction therapies in Japanese patients with lupus nephritis class III or IV: a single-centre retrospective study. PLoS One 2017; 12: e0175152. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthrit Care Res 2012; 64: 797-808.
  5. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dorner T, Doria A et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-1782.
  6. Mok CC, Yap DY, Navarra SV, Liu ZH, Zhao MH, Lu L, Takeuchi T, Avihingsanon Y, Yu XQ, Lapid EA et al. Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology 2014; 19: 11-20.
  7. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112.
  8. Weng MY, Weng CT, Liu MF. The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol 2010; 29: 771-775.
  9. Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, Shen P, Chen N. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transpl 2012; 27: 1467- 1472. Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001; 59: 2156-2163.
  10. Sloan RP, Schwartz MM, Korbet SM, Borok RZ. Long-ter